Treatment of Oncologic Emergencies in the Neurocritical Care Unit

  • Jeffrey S. Ehresman
  • Chetan BettegowdaEmail author
Part of the Current Clinical Neurology book series (CCNEU)


Neuro-oncologic patients are at high risk for many adverse events, and the severity of these events varies greatly. While some may only require monitoring in the neurointensive care unit (NCCU), others may be lethal if intervention is not performed immediately. Furthermore, some patients may be admitted with signs of neurologic pathology but have no known oncologic history. Rapid evaluation and diagnosis of these patients is vital in order to prevent the mortality and morbidity associated with neuro-oncologic emergencies. This allows the NCCU team to deliver the most effective treatments and to push for better patient outcomes. This chapter summarizes the presentation, hospital course, and management of four of the most common neuro-oncologic emergencies, including elevated intracranial pressure, pituitary tumor apoplexy, acute tumor hemorrhage, and status epilepticus.


Oncologic emergencies Neurosciences critical care unit Intracranial pressure Pituitary tumor apoplexy Acute tumor hemorrhage Status epilepticus 


  1. 1.
    Smith ER, Madsen JR. Cerebral pathophysiology and critical care neurology: basic hemodynamic principles, cerebral perfusion, and intracranial pressure. Semin Pediatr Neurol. 2004;11:89–104.CrossRefGoogle Scholar
  2. 2.
    Mokri B. The monro-kellie hypothesis: applications in CSF volume depletion. Neurology. 2001;56:1746–8.CrossRefGoogle Scholar
  3. 3.
    Lin AL, Avila EK. Neurologic emergencies in the patients with cancer. J Intensive Care Med. 2017;32:99–115. Scholar
  4. 4.
    Brandes AA, Tosoni A, Spagnolli F, Frezza G, Leonardi M, Calbucci F, et al. Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. Neuro-Oncology. 2008;10(3):361–7.CrossRefGoogle Scholar
  5. 5.
    Tremont-Lukats IW, Tummala S. Oncologic emergencies of the central nervous system (CNS). In: Todd K, Thomas Jr C, editors. Oncologic emergency medicine. Cham: Springer; 2016.Google Scholar
  6. 6.
    Forsyth PA, Posner JB. Headaches in patients with brain tumors: a study of 111 patients. Neurology. 1993;43(9):1678–83.CrossRefGoogle Scholar
  7. 7.
    Damek DM. Cerebral edema, altered mental status, seizures, acute stroke, leptomeningeal metastases, and paraneoplastic syndrome. Hematol Oncol Clin North Am. 2010;24:515–35. Scholar
  8. 8.
    Hayashi M, Kobayashi H, Handa Y, Kawano H, Kabuto M. Brain blood volume and blood flow in patients with plateau waves. J Neurosurg. 1985;63:556–61. Scholar
  9. 9.
    Magnaes B. Body position and cerebrospinal fluid pressure. Part 1: clinical studies on the effect of rapid postural changes. J Neurosurg. 1976;44:687–97. Scholar
  10. 10.
    Castellani G, Zweifel C, Kim DJ, et al. Plateau waves in head injured patients requiring neurocritical care. Neurocrit Care. 2009;11:143–50. Scholar
  11. 11.
    Rees JH. Diagnosis and treatment in neuro-oncology: an oncological perspective. Br J Radiol. 2011;84 Spec No 2:S82–9. Scholar
  12. 12.
    Scott BJ. Neuro-oncologic emergencies. Semin Neurol. 2015;35:675–82. Scholar
  13. 13.
    Pater K, Puskulluoglu M, Zygulska AL. Oncological emergencies: increased intracranial pressure in solid tumours’ metastatic brain disease. Przegl Lek. 2014;71(2):91–4.PubMedGoogle Scholar
  14. 14.
    Stevens RD, Shoykhet M, Cadena R. Emergency neurological life support: intracranial hypertension and herniation. Neurocrit Care. 2015;23(Suppl 2):S76–82. Scholar
  15. 15.
    Yumoto T, Mitsuhashi T, Yamakawa Y, et al. Impact of cushing’s sign in the prehospital setting on predicting the need for immediate neurosurgical intervention in trauma patients: a nationwide retrospective observational study. Scand J Trauma Resusc Emerg Med. 2016;24:147. Scholar
  16. 16.
    Wei S, Cao J, Feng L, Chen B, Feng J. Cheyne-stokes respiration. Zhonghua Jie He Hu Xi Za Zhi. 2014;37:53–5.Google Scholar
  17. 17.
    Marino R, Gasparotti R, Pinelli L, et al. Posttraumatic cerebral infarction in patients with moderate or severe head trauma. Neurology. 2006;67:1165–71. [pii].
  18. 18.
    Giacino JT, Smart CM. Recent advances in behavioral assessment of individuals with disorders of consciousness. Curr Opin Neurol. 2007;20:614–9. Scholar
  19. 19.
    Ropper AH, Gress DR, Diringer MN. Neurological and neurosurgical intensive care. Philadelphia: Wolters Kluwer; 2015.Google Scholar
  20. 20.
    Ryken TC, McDermott M, Robinson PD, et al. The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neuro-Oncol. 2010;96:103–14. Scholar
  21. 21.
    Kaal EC, Vecht CJ. The management of brain edema in brain tumors. Curr Opin Oncol. 2004;16:593–600. [pii]
  22. 22.
    Koenig MA, Bryan M, Lewin JL 3rd, Mirski MA, Geocadin RG, Stevens RD. Reversal of transtentorial herniation with hypertonic saline. Neurology. 2008;70:1023–9. Scholar
  23. 23.
    Jo JT, Schiff D. Management of neuro-oncologic emergencies. Handb Clin Neurol. 2017;141:715–41. [pii]
  24. 24.
    Boone MD, Oren-Grinberg A, Robinson TM, Chen CC, Kasper EM. Mannitol or hypertonic saline in the setting of traumatic brain injury: What have we learned? Surg Neurol Int. 2015;6:177. –7806.170248. eCollection 2015. Scholar
  25. 25.
    Quinn JA, DeAngelis LM. Neurologic emergencies in the cancer patient. Semin Oncol. 2000;27:311–21.PubMedGoogle Scholar
  26. 26.
    Wakai S, Fukushima T, Teramoto A, Sano K. Pituitary apoplexy: its incidence and clinical significance. J Neurosurg. 1981;55:187–93. Scholar
  27. 27.
    Johnston PC, Hamrahian AH, Weil RJ, Kennedy L. Pituitary tumor apoplexy. J Clin Neurosci. 2015;22:939–44. Scholar
  28. 28.
    Verrees M, Arafah BM, Selman WR. Pituitary tumor apoplexy: characteristics, treatment, and outcomes. Neurosurg Focus. 2004;16:E6. [pii]
  29. 29.
    Lubina A, Olchovsky D, Berezin M, Ram Z, Hadani M, Shimon I. Management of pituitary apoplexy: clinical experience with 40 patients. Acta Neurochir (Wien). 2005;147:151–7. ; discussion 157. Scholar
  30. 30.
    Dubuisson AS, Beckers A, Stevenaert A. Classical pituitary tumour apoplexy: clinical features, management and outcomes in a series of 24 patients. Clin Neurol Neurosurg. 2007;109:63–70. [pii]
  31. 31.
    Randeva HS, Schoebel J, Byrne J, Esiri M, Adams CB, Wass JA. Classical pituitary apoplexy: clinical features, management and outcome. Clin Endocrinol. 1999;51:181–8. [pii]
  32. 32.
    Turgut M, Ozsunar Y, Basak S, Guney E, Kir E, Meteoglu I. Pituitary apoplexy: an overview of 186 cases published during the last century. Acta Neurochir. 2010;152:749–61. Scholar
  33. 33.
    Baldeweg SE, Vanderpump M, Drake W, et al. Society For Endocrinology Endocrine Emergency Guidance: emergency management of pituitary apoplexy in adult patients. Endocr Connect. 2016;5:G12–5. [pii].
  34. 34.
    Singh TD, Valizadeh N, Meyer FB, Atkinson JL, Erickson D, Rabinstein AA. Management and outcomes of pituitary apoplexy. J Neurosurg. 2015;122:1450–7. Scholar
  35. 35.
    Ranabir S, Baruah MP. Pituitary apoplexy. Indian J Endocrinol Metab. 2011;15(Suppl 3):S188–96. Scholar
  36. 36.
    Gruber A, Clayton J, Kumar S, Robertson I, Howlett TA, Mansell P. Pituitary apoplexy: retrospective review of 30 patients–is surgical intervention always necessary? Br J Neurosurg. 2006;20:379–85.CrossRefGoogle Scholar
  37. 37.
    Ayuk J, McGregor EJ, Mitchell RD, Gittoes NJ. Acute management of pituitary apoplexy–surgery or conservative management? Clin Endocrinol. 2004;61:747–52. [pii]
  38. 38.
    Rajasekaran S, Vanderpump M, Baldeweg S, et al. UK guidelines for the management of pituitary apoplexy. Clin Endocrinol. 2011;74:9–20. Scholar
  39. 39.
    Kamel H, Navi BB, Hemphill JC 3rd. A rule to identify patients who require magnetic resonance imaging after intracerebral hemorrhage. Neurocrit Care. 2013;18:59–63. Scholar
  40. 40.
    Schrader B, Barth H, Lang EW, et al. Spontaneous intracranial haematomas caused by neoplasms. Acta Neurochir. 2000;142:979–85.CrossRefGoogle Scholar
  41. 41.
    Licata B, Turazzi S. Bleeding cerebral neoplasms with symptomatic hematoma. J Neurosurg Sci. 2003;47:201–10.. discussion 210PubMedGoogle Scholar
  42. 42.
    Liwnicz BH, Wu SZ, Tew JM Jr. The relationship between the capillary structure and hemorrhage in gliomas. J Neurosurg. 1987;66:536–41. Scholar
  43. 43.
    Navi BB, Reichman JS, Berlin D, et al. Intracerebral and subarachnoid hemorrhage in patients with cancer. Neurology. 2010;74:494–501. Scholar
  44. 44.
    Velander AJ, DeAngelis LM, Navi BB. Intracranial hemorrhage in patients with cancer. Curr Atheroscler Rep. 2012;14:373–81. Scholar
  45. 45.
    3rd Hemphill JC, Greenberg SM, Anderson CS, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the american heart association/American stroke association. Stroke. 2015;46:2032–60. Scholar
  46. 46.
    Mendelow AD, Gregson BA, Fernandes HM, et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the international surgical trial in intracerebral haemorrhage (STICH): a randomised trial. Lancet. 2005;365:387–97.–6736(05)17826-X [pii].
  47. 47.
    Mendelow AD, Gregson BA, Rowan EN, et al. Early surgery versus initial conservative treatment in patients with traumatic intracerebral hemorrhage (STITCH[trauma]): the first randomized trial. J Neurotrauma. 2015;32:1312–23. Scholar
  48. 48.
    Ruda R, Bello L, Duffau H, Soffietti R. Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments. Neuro Oncol. 2012;14 Suppl 4:iv55–64. Scholar
  49. 49.
    Baldwin KJ, Zivkovic SA, Lieberman FS. Neurologic emergencies in patients who have cancer: diagnosis and management. Neurol Clin. 2012;30:101–28, viii. Scholar
  50. 50.
    Kerkhof M, Vecht CJ. Seizure characteristics and prognostic factors of gliomas. Epilepsia. 2013;54(Suppl 9):12–7. Scholar
  51. 51.
    van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol. 2007;6:421–30.–4422(07)70103–5 [pii].
  52. 52.
    Maschio M. Brain tumor-related epilepsy. Curr Neuropharmacol. 2012;10:124–33. Scholar
  53. 53.
    Alldredge BK, Lowenstein DH. Status epilepticus: new concepts. Curr Opin Neurol. 1999;12:183–90.CrossRefGoogle Scholar
  54. 54.
    Cavaliere R, Farace E, Schiff D. Clinical implications of status epilepticus in patients with neoplasms. Arch Neurol. 2006;63:1746–9. [pii].
  55. 55.
    Goonawardena J, Marshman LA, Drummond KJ. Brain tumour-associated status epilepticus. J Clin Neurosci. 2015;22:29–34. Scholar
  56. 56.
    Lee EQ, Arrillaga-Romany IC, Wen PY. Neurologic complications of cancer drug therapies. Continuum (Minneap Minn). 2012;18:355–65. Scholar
  57. 57.
    Damek DM. Cerebral edema, altered mental status, seizures, acute stroke, leptomeningeal metastases, and paraneoplastic syndrome. Hematol Oncol Clin North Am. 2010;24:515–35. Scholar
  58. 58.
    Treiman DM, Meyers PD, Walton NY, et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans affairs status epilepticus cooperative study group. N Engl J Med. 1998;339:792–8. Scholar
  59. 59.
    Silbergleit R, Durkalski V, Lowenstein D, et al. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med. 2012;366:591–600. Scholar
  60. 60.
    Brophy GM, Bell R, Claassen J, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17:3–23. Scholar
  61. 61.
    Usery JB, 2nd Michael LM, Sills AK, Finch CK. A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures. J Neuro-Oncol. 2010;99:251–60. Scholar
  62. 62.
    Saria MG, Corle C, Hu J, et al. Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors: clinical article. J Neurosurg. 2013;118:1183–7. Scholar
  63. 63.
    Bourg V, Lebrun C, Chichmanian RM, Thomas P, Frenay M. Nitroso-urea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity. Ann Oncol. 2001;12:217–9.CrossRefGoogle Scholar
  64. 64.
    Glantz MJ, Cole BF, Forsyth PA, Recht LD, Wen PY, Chamberlain MC, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;54(10):1886–93.CrossRefGoogle Scholar
  65. 65.
    Marcuse LV, Lancman G, Demopoulos A, Fields M. Nonconvulsive status epilepticus in patients with brain tumors. Seizure. 2014;23:542–7. Scholar
  66. 66.
    Chang EF, Potts MB, Keles GE, et al. Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg. 2008;108:227–35. Scholar
  67. 67.
    China Neurosurgical Critical Care Specialist Council (CNCCSC), Zhao JZ, Zhou DB, et al. The experts consensus for patient management of neurosurgical critical care unit in China. Chin Med J. 2015;128:1252–67. Scholar
  68. 68.
    Ziai WC, Melnychuk E, Thompson CB, Awad I, Lane K, Hanley DF. Occurrence and impact of intracranial pressure elevation during treatment of severe intraventricular hemorrhage. Crit Care Med. 2012;40:1601–8. Scholar
  69. 69.
    Isley MR, Jr Edmonds HL, Stecker M, American Society of Neurophysiological Monitoring. Guidelines for intraoperative neuromonitoring using raw (analog or digital waveforms) and quantitative electroencephalography: a position statement by the american society of neurophysiological monitoring. J Clin Monit Comput. 2009;23:369–90. Scholar
  70. 70.
    Luetz A, Balzer F, Radtke FM, et al. Delirium, sedation and analgesia in the intensive care unit: a multinational, two-part survey among intensivists. PLoS One. 2014;9:e110935. Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of NeurosurgeryJohns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations